These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19160525)

  • 1. Selective inhibition of acyl-CoA:cholesterol acyltransferase 2 isozyme by flavasperone and sterigmatocystin from Aspergillus species.
    Sakai K; Ohte S; Ohshiro T; Matsuda D; Masuma R; Rudel LL; Tomoda H
    J Antibiot (Tokyo); 2008 Sep; 61(9):568-72. PubMed ID: 19160525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectivity of pyripyropene derivatives in inhibition toward acyl-CoA:cholesterol acyltransferase 2 isozyme.
    Ohshiro T; Ohte S; Matsuda D; Ohtawa M; Nagamitsu T; Sunazuka T; Harigaya Y; Rudel LL; Omura S; Tomoda H
    J Antibiot (Tokyo); 2008 Aug; 61(8):503-8. PubMed ID: 18997389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectivity of microbial acyl-CoA: cholesterol acyltransferase inhibitors toward isozymes.
    Ohshiro T; Rudel LL; Omura S; Tomoda H
    J Antibiot (Tokyo); 2007 Jan; 60(1):43-51. PubMed ID: 17390588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and combinatorial synthesis of fungal metabolites beauveriolides, novel antiatherosclerotic agents.
    Tomoda H; Doi T
    Acc Chem Res; 2008 Jan; 41(1):32-9. PubMed ID: 17803269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selectivity of beauveriolide derivatives in inhibition toward the two isozymes of acyl-CoA: cholesterol acyltransferase.
    Ohshiro T; Matsuda D; Nagai K; Doi T; Sunazuka T; Takahashi T; Rudel LL; Omura S; Tomoda H
    Chem Pharm Bull (Tokyo); 2009 Apr; 57(4):377-81. PubMed ID: 19336931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New verticilides, inhibitors of acyl-CoA:cholesterol acyltransferase, produced by Verticillium sp. FKI-2679.
    Ohshiro T; Matsuda D; Kazuhiro T; Uchida R; Nonaka K; Masuma R; Tomoda H
    J Antibiot (Tokyo); 2012 May; 65(5):255-62. PubMed ID: 22415459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?
    López-Farré AJ; Sacristán D; Zamorano-León JJ; San-Martín N; Macaya C
    Cardiovasc Ther; 2008; 26(1):65-74. PubMed ID: 18466422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical role for the histidine residues in the catalytic function of acyl-CoA:cholesterol acyltransferase catalysis: evidence for catalytic difference between ACAT1 and ACAT2.
    An S; Cho KH; Lee WS; Lee JO; Paik YK; Jeong TS
    FEBS Lett; 2006 May; 580(11):2741-9. PubMed ID: 16647063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of acyl CoA:cholesterol acyltransferase.
    Vaccaro W; Amore C; Berger J; Burrier R; Clader J; Davis H; Domalski M; Fevig T; Salisbury B; Sher R
    J Med Chem; 1996 Apr; 39(8):1704-19. PubMed ID: 8648610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoform-specific inhibitors of ACATs: recent advances and promising developments.
    Ohshiro T; Tomoda H
    Future Med Chem; 2011 Dec; 3(16):2039-61. PubMed ID: 22098352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 1.
    Ohtawa M; Yamazaki H; Ohte S; Matsuda D; Ohshiro T; Rudel LL; Omura S; Tomoda H; Nagamitsu T
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1285-7. PubMed ID: 23369538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness.
    Lada AT; Davis M; Kent C; Chapman J; Tomoda H; Omura S; Rudel LL
    J Lipid Res; 2004 Feb; 45(2):378-86. PubMed ID: 14617738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-Chlorofolipastatin, an inhibitor of sterol O-acyltransferase, produced by marine-derived Aspergillus ungui NKH-007.
    Uchida R; Nakajyo K; Kobayashi K; Ohshiro T; Terahara T; Imada C; Tomoda H
    J Antibiot (Tokyo); 2016 Aug; 69(8):647-51. PubMed ID: 26980608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glibenclamide acts as an inhibitor of acyl-CoA:cholesterol acyltransferase enzyme.
    Ohgami N; Kuniyasu A; Furukawa K; Miyazaki A; Hakamata H; Horiuchi S; Nakayama H
    Biochem Biophys Res Commun; 2000 Oct; 277(2):417-22. PubMed ID: 11032738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acyl-CoA : cholesterol acyltransferase inhibitors from Magnolia obovata.
    Kwon BM; Kim MK; Lee SH; Kim JA; Lee IR; Kim YK; Bok SH
    Planta Med; 1997 Dec; 63(6):550-1. PubMed ID: 9434609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penicillium griseofulvum F1959, high-production strain of pyripyropene a, specific inhibitor of acyl-CoA: cholesterol acyltransferase 2.
    Choi JH; Rho MC; Lee SW; Choi JN; Lee HJ; Bae KS; Kim K; Kim YK
    J Microbiol Biotechnol; 2008 Oct; 18(10):1663-5. PubMed ID: 18955816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular target of rubimaillin in the inhibition of lipid droplet accumulation in macrophages.
    Matsuda D; Ohshiro T; Ohba M; Jiang W; Hong B; Si S; Tomoda H
    Biol Pharm Bull; 2009 Aug; 32(8):1317-20. PubMed ID: 19652367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 3.
    Ohtawa M; Yamazaki H; Ohte S; Matsuda D; Ohshiro T; Rudel LL; Ōmura S; Tomoda H; Nagamitsu T
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3798-801. PubMed ID: 23711919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia.
    Rudel LL; Lee RG; Parini P
    Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1112-8. PubMed ID: 15831806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential therapeutics for obesity and atherosclerosis: inhibitors of neutral lipid metabolism from microorganisms.
    Tomoda H; Omura S
    Pharmacol Ther; 2007 Sep; 115(3):375-89. PubMed ID: 17614133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.